In vitro trials in both lung and breast cancers indicated that FGFR-TKI enhances infiltration of CD4+ helper T-cells and CD8+ effector T-cells and inhibits the generation of Treg cells and end-depleted T-cells [23, 114, 115]. The gene discussed is CD8A; the disease is breast cancer.